Beactica to collaborate on fragment-based drug discovery
Beactica, a Swedish fragment-based drug discovery company, is to collaborate with UK-based GE Healthcare and Uppsala University in Sweden on fragment-based drug discovery.
Beactica, a Swedish fragment-based drug discovery company, is to collaborate with UK-based GE Healthcare and Uppsala University in Sweden on fragment-based drug discovery.
The collaboration will combine Beactica's fragment-based discovery and GE Healthcare's Biacore technology with enzymology expertise from Uppsala University.
The consortium will develop the next-generation of Biacore surface plasmon resonance instruments and applications for fragment-based drug discovery. The project also aims to identify novel high-quality leads against a clinically important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.
Dr Per Kallblad, chief executive of Beactica, said: "The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next-generation applications from GE Healthcare will enable us to stay at the forefront of our field."